THNR vs. CSHP
THNR (Amplify Weight Loss Drug & Treatment ETF) and CSHP (iShares Enhanced Short-Term Bond Active ETF) are both exchange-traded funds - THNR is a Health & Biotech Equities fund tracking the VettaFi Weight Loss Drug & Treatment Index, while CSHP is a Ultrashort Bond fund actively managed by iShares. THNR is passively managed, while CSHP is actively managed. Over the past year, THNR returned 12.04% vs 3.94% for CSHP. At a correlation of -0.00, they often move in opposite directions. THNR charges 0.59%/yr vs 0.20%/yr for CSHP.
Performance
THNR vs. CSHP - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, THNR achieves a -2.16% return, which is significantly lower than CSHP's 1.83% return.
THNR
- 1D
- 0.96%
- 1M
- -0.39%
- YTD
- -2.16%
- 6M
- -3.36%
- 1Y
- 12.04%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
CSHP
- 1D
- -0.03%
- 1M
- 0.27%
- YTD
- 1.83%
- 6M
- 1.92%
- 1Y
- 3.94%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
THNR vs. CSHP - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
THNR Amplify Weight Loss Drug & Treatment ETF | -2.16% | 13.65% | -14.28% |
CSHP iShares Enhanced Short-Term Bond Active ETF | 1.83% | 4.10% | 2.24% |
Correlation
The correlation between THNR and CSHP is -0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.09 |
Correlation (All Time) Calculated using the full available price history since Jul 18, 2024 | -0.00 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
THNR vs. CSHP — Risk / Return Rank
THNR
CSHP
THNR vs. CSHP - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Amplify Weight Loss Drug & Treatment ETF (THNR) and iShares Enhanced Short-Term Bond Active ETF (CSHP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| THNR | CSHP | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -10.45 | ||
| Sortino ratioReturn per unit of downside risk | -26.55 | ||
| Omega ratioGain probability vs. loss probability | 1.12 | 6.46 | -5.33 |
| Calmar ratioReturn relative to maximum drawdown | 1.00 | 65.45 | -64.45 |
| Martin ratioReturn relative to average drawdown | 2.20 | 381.67 | -379.47 |
Loading charts...
Drawdowns
THNR vs. CSHP - Drawdown Comparison
The maximum THNR drawdown since its inception was -32.51%, which is greater than CSHP's maximum drawdown of -0.08%. Use the drawdown chart below to compare losses from any high point for THNR and CSHP.
Loading charts...
Drawdown Indicators
| THNR | CSHP | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -32.51% | -0.08% | -32.43% |
Max Drawdown (1Y)Largest decline over 1 year | -12.06% | -0.06% | -12.00% |
Current DrawdownCurrent decline from peak | -10.21% | -0.04% | -10.17% |
Average DrawdownAverage peak-to-trough decline | -12.21% | -0.00% | -12.21% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.48% | 0.01% | +5.47% |
Volatility
THNR vs. CSHP - Volatility Comparison
Amplify Weight Loss Drug & Treatment ETF (THNR) has a higher volatility of 5.73% compared to iShares Enhanced Short-Term Bond Active ETF (CSHP) at 0.16%. This indicates that THNR's price experiences larger fluctuations and is considered to be riskier than CSHP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| THNR | CSHP | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.73% | 0.16% | +5.57% |
Volatility (6M)Calculated over the trailing 6-month period | 13.69% | 0.27% | +13.42% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.03% | 0.36% | +18.67% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 19.34% | 0.41% | +18.93% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 19.34% | 0.41% | +18.93% |
THNR vs. CSHP - Expense Ratio Comparison
THNR has a 0.59% expense ratio, which is higher than CSHP's 0.20% expense ratio.
Dividends
THNR vs. CSHP - Dividend Comparison
THNR's dividend yield for the trailing twelve months is around 1.67%, less than CSHP's 3.91% yield.
| Position | TTM | 2025 | 2024 |
|---|---|---|---|
CSHP iShares Enhanced Short-Term Bond Active ETF | 3.91% | 5.39% | 1.96% |
THNR Amplify Weight Loss Drug & Treatment ETF | 1.67% | 1.64% | 0.98% |
Frequently Asked Questions
THNR and CSHP have a correlation of -0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
THNR has higher volatility (5.73%) compared to CSHP (0.16%). In terms of maximum drawdown, THNR dropped -32.51% vs CSHP's -0.08%.
On 1-year performance, THNR leads with 12.04% vs 3.94% for CSHP. On fees, CSHP is cheaper at 0.20% per year. On volatility, CSHP has been the lower-risk option at 0.16%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 1-year period, THNR has performed better with a 12.04% return vs 3.94%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
CSHP is cheaper with a 0.20% expense ratio, compared with 0.59% for THNR.
CSHP has the higher dividend yield at 3.91%, compared with 1.67% for THNR.
THNR is categorized as Health & Biotech Equities, while CSHP is Ultrashort Bond. They also come from different issuers: Amplify and iShares. Their fees differ too: 0.59% for THNR and 0.20% for CSHP.
CSHP currently has the higher Sharpe Ratio (11.09 vs 0.64), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for THNR and CSHP
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer